A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies

Inclusion Criteria:

1. Males and females greater than or equal to 18 years of age

2. Life expectancy of at least 3 months

3. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1

4. Diagnosis of histopathologically confirmed hematologic malignancies. For NHL:
Confirmed B-cell NHL (as per the World Health Organization [WHO] 2016 classification
including WM/LPL). For AML: Diagnosis of histopathologically confirmed AML (as per the
World Health Organization [WHO] 2016 classification; Owen 2013) that is relapsed
and/or refractory.

5. Relapsed or refractory disease for which patients are ineligible for or have exhausted
standard therapeutic options that would be considered standard of care

Exclusion Criteria:

1. Active central nervous system (CNS) involvement of their malignancy.

2. Radiotherapy delivered to non-target lesions within one week prior to starting study
treatment or delivered to target lesions that will be followed on the study (NOTE:
prior sites of radiation will be recorded)

3. History of allogeneic stem cell transplant for NHL

4. Any prior anti-cancer treatment such as chemotherapy, immunomodulatory drug therapy,
etc., received within 14 days prior to start of CA-4948

5. Current or planned glucocorticoid therapy, with the following exceptions:

1. Doses ≤ 10 mg/day prednisolone or equivalent is allowed, provided that the
steroid dose has been stable or tapering for at least 14 days prior to the first
dose of CA-4948

2. Inhaled, intranasal, intraarticular and topical steroids are permitted

6. Use of any investigational agent within 28 days or 5 half-lives, whichever is shorter,
prior to start of CA-4948

7. Presence of an acute or chronic toxicity resulting from prior anti-cancer therapy,
with the exception of alopecia, that has not resolved to Grade ≤ 1 within 7 days prior
to start of CA-4948 unless approved by the Medical Monitor

8. Known allergy or hypersensitivity to any component of the formulation of CA-4948 used
in this study

9. Diagnosis of acute promyelocytic leukemia (APL, M3) for AML

10. Hematopoietic stem cell transplant (HSCT) within 60 days of the first dose of CA-4948
for AML

11. Blast transformation of CML into AML